All In Biotech

Drug Trial Radar · NCT07826455

A Study to Evaluate Tegoprazan as a Diagnostic Tool for GERD

Diagnostic Value of Early Response to Tegoprazan in Symptomatic GERD Patients: An Exploratory Clinical Study

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Jul 31, 2028

Study completion Jul 31, 2028

Sponsor

Lead sponsor
HK inno.N CorporationIndustry
Sponsor type
Industry
First posted
Sep 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the diagnostic value of tegoprazan for GERD. Patients experiencing typical GERD symptoms, such as heartburn and acid regurgitation, will take either tegoprazan or a placebo once daily for 1 week. Investigators will compare the short-term symptom improvement between the two groups to determine if an early response to tegoprazan can help diagnose GERD.

Conditions

  • GERD (Gastroesophageal Reflux Disease)

Interventions

  • Tegoprazan 50 mgDrug

    Tegoprazan 50 mg tablet will be orally administered once daily for 7 days.

  • PlaceboDrug

    Placebo tablet will be orally administered once daily for 7 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Diagnostic accuracy (Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value) of GERD based on total symptom scoreTime frame: Day 7

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.